Roche paid $400 million upfront, plus $115 million on the first anniversary, for ex-China rights to two preclinical ADCs and $15 billion in milestones. Stephen Hansen notes Novartis, Novo and Merck recently signed similar early China deals; Jeff Cranmer says Hanso will run Phase 1A before Roche takes over.
Selina Koch says Order 818 took effect in May and enforcement surprised Dan Zhang: 7,000 IIT applications produced fewer than 100 approvals in two months, and eligible hospitals fell from 250,000 to 1,800. Jing Pan says solid CMC data can still get quick approval at her 1,500-bed hospital.
Selina Koch says Arrowhead's healthy-volunteer data showed up to 73% tau knockdown, a first for siRNA in people. But Biogen's intrathecal antisense showed more knockdown at higher doses without matching efficacy; the lowest dose worked best, raising whether excess tau knockdown is harmful; patient data are needed.
Stephen Hansen says Bloomberg-reported talks would value Isomorphic Labs, a Google DeepMind spinout, at $40 billion to $50 billion, after a $2.1 billion May raise at a rumored $10 billion-$17 billion. Tech investors likely compare it with Anthropic or OpenAI, forcing near-perfect pipeline execution to justify that price.
Roche's second China-to-West ALK7 siRNA deal with Rona follows Arrowhead's Phase 1 data showing adipose-tissue knockdown. Stephen Hansen says ALK7 is not a liver target, so companies must solve delivery to fat tissue; Simone Fishburne says RNAi's clinical validation lets China biotechs take biology risk.
Josh Berlin says China's MOFCOM proposal on export controls could hit cell and gene therapy and siRNA deals; it is open for comment, not final. BioCentury is adding a late-breaking China summit session on it and the China 2030 biopharma blueprint because policy moves at China speed.
